檔案名稱:rp-1/rHuIL1ra.html

重組蛋白目錄

本類目錄


Recombinant Human Interleukin-1 receptor antagonist

Certificate of Analysis and Data Sheet

Source:
E.Coli

Catalog No.
CYT-203

Background:

Interleukin-1 receptor antagonist (IL-1ra) is a member of the IL-1 family. Endogenous IL-1ra is produced in numerous animal disease models as well as in human autoimmune and chronic inflammatory diseases. It binds to IL-1 receptors in competition with IL-1, but does not elicit intracellular response from this binding. Its role in counteracting the proinflammatory effects of IL-1 is being studied by numerous research groups.
IL-4 and IL-13 have been shown to amplify the stimulatory effect of IL1-beta on the production of soluble and intracellular forms of IL1-ra.
The regulated expression of IL1ra in various cell types has been shown to be influenced by cytokines. In synovial fibroblasts the synthesis of IL-1ra is markedly enhanced by IL-1 , TNF-alpha , or PDGF.

Description :

Recombinant Human IL-1ra produced in E.Coli is a non-glycosylated, N-terminal methionyl form of the human naturally-occurring polypeptide chain containing 153amino acids and having a molecular mass of 17000 Dalton Recombinant IL-1ra is purified by proprietary chromatographic techniques.

Physical Appearance:

Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation:

Lyophilized protein with no additives.

Solubility:

It is recommended to reconstitute the lyophilized IL-1ra in sterile 18Mω-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.

Stability:

Lyophilized IL-1ra although stable at room temperature for 3 weeks, should be stored desiccated below -18 C. Upon reconstitution IL-1ra should be stored at 4 C between 2-7 days and for future use below -18 C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Please avoid freeze-thaw cycles.

Purity:

Greater than 98.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Anion-exchange FPLC.
(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel.

Amino acid sequence:

The sequence of the first five N-terminal amino acids was determined and was found to be Met-Arg-Pro-Ser-Gly.

Dimers and aggregates:

Less than 1% as determined by silver-stained SDS-PAGE gel analysis.

Biological Activity:

ProSpec's Interleukin-1ra is fully biologically active when compared to standard. The ED50 as determined by the dose-dependant inhibition of IL-1 stimulation of D10S cells was found to be 0.5 ng/ml.

Endotoxin:

Less than 0.1 ng/ug (IEU/ug) of IL-1ra.

Protein content:

Protein quantitation was carried out by two independent methods:
1. UV spectroscopy at 280 nm using the absorbency value of 0.89 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics).
2. Analysis by RP-HPLC, using a standard solution of IL-1ra as a Reference Standard.

Usage:

This material is offered by ProSpec-TechnoGene for research, laboratory or further evaluation purposes.


Gene:

Name:IL1RN
Synonyms:IL1F3, IL1RA

Protein synonyms/aliases:

Interleukin-1 receptor antagonist protein precursor (IL-1ra)
    (IRAP)
    (IL1 inhibitor)
    (IL-1RN)
    (ICIL-1RA).

Protein Family:

Belongs to the IL-1 family.

Protein Domains:


Domains:
IPR000975   Interleukin-1

Related proteins:

Recombinant Human Interleukin-18
Recombinant Mouse Interleukin-18
Recombinant Rat Interleukin-18
Recombinant Human Interleukin-1 alpha
Recombinant Human Interleukin-1 beta
Recombinant Murine Interleukin-1 beta

Protein links:

Recombinant Human Interleukin-1 receptor antagonist protein domain

Recombinant Human Interleukin-1 receptor antagonist protein family


Precursor- Protein structure and amino acid sequence:


Latest Publications:

1. A preliminary in vitro study into the use of IL-1Ra gene therapy for the inhibition of intervertebral disc degeneration.
Int J Exp Pathol 2006 Feb;87(1):17-28
2. Ethnicity Greatly Influences the Interleukin-1 Gene Cluster(IL-1b Promoter, Exon-5 and IL-1Ra) Polymorphisms: A Pilot Study of a North Indian Population.
Asian Pac J Cancer Prev 2005 Oct-Dec;6(4):541-6
3. Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1ra) are mediated by glia.
Glia 2006 Apr 1;53(5):551-6
4. Effects of soluble TNF receptor II (sTNF-RII), IL-1 receptor antagonist (IL-1ra), tumor load and hypermetabolism on malnutrition in children with acute leukemia.
Eur J Med Res 2005 Nov 16;10(11):457-61
5. [Effects of immunoglobulin on the neuronal expression of IL-1beta and IL-1ra and the neuronal death at hippocampus in rats with convulsion induced by pentylenetetrazol]
Zhonghua Er Ke Za Zhi 2005 Nov;43(11):849-51
6. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
Ann Rheum Dis 2005 Nov;64 Suppl 4:iv2-14

採購找生工,預算最輕鬆。

回頁首↑ | 回首頁←


中華民國95年06月06日更新